Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SLOW-K is an extended-release oral tablet containing potassium, approved in 1975 as a small-molecule NDA by Novartis. The drug is indicated for potassium supplementation and electrolyte management in patients requiring sustained potassium levels. It operates through direct mineral supplementation to restore or maintain serum potassium concentrations.
As LOE approaches, the brand team is likely in defensive-positioning mode with focus on retention strategies and cost containment rather than market expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SLOW-K offers limited career growth due to zero linked job openings and LOE approaching status. Professionals assigned to this product are likely managing decline, optimizing profitability, and preparing transition strategies rather than driving innovation or market expansion.
Worked on SLOW-K at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.